Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Researchers Devising Creative Solutions to the Challenges of Developing Oral Biologics

Posted on March 28th, 2019 by in Pharma R&D

Many biologic drugs with household names like Humira, Enbrel and Neulasta are protein-based drugs derived from living organisms that treat a wide range of diseases. While deliver complications have typically been administered via injection, there is an increasing trend in the Pharma R&D community to experiment with oral biologics, or an injection in pill form.

(more…)

As Drug Development Costs Skyrocket, AI Offers Some Hope

Posted on November 20th, 2017 by in Pharma R&D

Last year, researchers from the Tufts Center for the Study of Drug Development published a paper in the Journal of Health Economics that provided an assessment of the current cost for pharmaceutical companies to discover and develop new drugs and biologics. (more…)

Start-up Spotlight: Proteios

Posted on November 11th, 2016 by in Pharma R&D

This week’s Start-Up Spotlight, featuring start-ups in the pharmaceutical and biotech spaces, is showcasing the Seattle-based firm Proteios. Dr. Bob Snyder, Managing Director of Proteios, discusses the company and its game-changing research. (more…)

Biosimilars and Pharmacovigilance: What You Need to Know—and Do—Now

Posted on April 26th, 2016 by in Pharmacovigilance

A few weeks ago, the US FDA approved Inflectra (infliximab-dyyb), a biosimilar to infliximab. This is the second US biosimilar approval, suggesting others may soon be on the way—good news for companies with biosimilars pending approval and in development. (more…)